Alphatec (NASDAQ:ATEC) is scheduled to be releasing its earnings data after the market closes on Wednesday, October 30th. Analysts expect Alphatec to post earnings of ($0.23) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.
Alphatec (NASDAQ:ATEC) last issued its earnings results on Wednesday, July 24th. The medical technology company reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.05). The firm had revenue of $27.32 million during the quarter, compared to analysts’ expectations of $25.37 million. Alphatec had a negative net margin of 45.29% and a negative return on equity of 211.15%. On average, analysts expect Alphatec to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of NASDAQ ATEC opened at $5.70 on Wednesday. The business’s 50 day moving average price is $5.26 and its 200 day moving average price is $4.57. The firm has a market cap of $329.02 million, a P/E ratio of -9.83 and a beta of 1.43. Alphatec has a 52 week low of $1.18 and a 52 week high of $6.35. The company has a quick ratio of 1.40, a current ratio of 2.45 and a debt-to-equity ratio of 3.59.
A number of brokerages recently commented on ATEC. Canaccord Genuity began coverage on Alphatec in a research report on Wednesday, August 28th. They issued a “buy” rating and a $7.00 target price on the stock. HC Wainwright upped their target price on Alphatec from $4.00 to $6.00 and gave the company a “buy” rating in a research report on Tuesday, August 6th. BidaskClub upgraded Alphatec from a “hold” rating to a “buy” rating in a research report on Saturday. ValuEngine lowered Alphatec from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Piper Jaffray Companies began coverage on Alphatec in a research report on Monday, August 5th. They issued an “overweight” rating and a $7.00 target price on the stock. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $6.67.
Alphatec Company Profile
Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures.
Further Reading: Why do companies issue stock splits?
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.